Cancer Currents: An NCI Cancer Research Blog
A blog featuring news and research updates from the National Cancer Institute. Learn more about Cancer Currents.
-
New Approach May Help People with Cancer Better Manage Depression, Pain, and FatigueAssessing and offering people with cancer stepped collaborative care may help better manage symptoms of depression, pain, and fatigue than the standard referral to providers for treatment, according to a recent study.
-
Blood Test Accurately Detects Early-Stage Pancreatic CancerIn a new study involving nearly 1,000 people, a liquid biopsy accurately detected early- and late-stage pancreatic cancer. When paired with a test for the protein CA19-9, the combination accurately identified 97% of people with early-stage disease.
-
Alectinib Approved as an Adjuvant Treatment for Lung CancerFDA has approved alectinib (Alecensa) as adjuvant therapy for people with lung cancer who have ALK-positive tumors. In a clinical trial, alectinib helped people live longer after surgery without their cancer returning than chemotherapy.
-
FDA Approves Trastuzumab Deruxtecan for Any HER2-Positive Solid CancerTrastuzumab deruxtecan (Enhertu) can now be used to treat any advanced solid cancer that produces high levels of the protein HER2 (HER2-positive tumors). FDA’s accelerated approval was based on findings from three clinical trials.
-
Q&A: Learning About the Cancer Care Challenges LGBTQ+ People FaceGwendolyn Quinn, Ph.D., a health psychologist at NYU Langone Health Perlmutter Cancer Center, discusses the challenges faced by sexual and gender minority people being treated for cancer and ways to address them.
-
LGBTQ+ Voices: Listening to Sexual and Gender Minority People Affected by CancerLGBTQ+ people, also known as sexual and gender minorities (SGM), with cancer may face challenges that non-SGM people do not face. The breadth and depth of these disparities aren't well known, but there’s growing research on the challenges this diverse group faces.
-
Approval of Elahere Expands Treatment Options for Some Advanced Ovarian CancersFDA approved mirvetuximab soravtansine-gynx (Elahere) to treat people with advanced, platinum-resistant ovarian cancer whose tumors overproduce a protein called FR-α. The full approval was based on the results of a large, randomized trial called MIRASOL, which showed Elahere improved survival for these people.
-
Scientists Link a Single Type of Bacteria to Colorectal CancerNCI-funded researchers have pinpointed a single type of the bacterium F. nucleatum that appears to fuel the development and growth of colorectal cancer. In mice, the bacterium, Fna C2, appeared to cause more adenomas to form in the large intestine and it was often found in human tumor samples.
-
Studies Assess Impact of Cancer Risk-Reduction Measures for People with BRCA ChangesFor women with inherited changes in the BRCA1 or BRCA2 genes, regular MRI scans and undergoing a surgery called a salpingo-oophorectomy appear to lower their chances of dying from breast and ovarian cancer, according to results from two studies.
-
New on NCI’s Websites for April 2024NCI periodically provides updates on new websites and other online content of interest to the cancer community. See selected content that has been added as of April 2024.
-
Drug Combination May Have Potential for Cancers with TP53 MutationsAlthough TP53 mutations help drive the growth of most cancers, there are no FDA-approved therapies that target altered p53 proteins. Now a drug combination has shown promise in mice and is being tested in a clinical trial.
-
Stress-Induced Immune Changes May Help Cancer SpreadStress-induced hormones called glucocorticoids can cause biological changes—in the form of sticky traps called NETs—that help create hospitable environments for cancer cells to form metastatic tumors, according to new research done largely in mice.
-
Rusfertide Nearly Eliminates Need for Phlebotomies to Treat Polycythemia VeraAdding rusfertide to treatment for polycythemia vera cut phlebotomy rates from nine to less than one per year in a recent clinical trial. The finding may improve the quality of life for those who manage the blood cancer with frequent blood draws.
-
Simple Hysterectomy May Expand Treatment Options for Early-Stage Cervical CancerFor some people with early-stage cervical cancer, a surgical procedure called a simple hysterectomy may be a safe and effective alternative to treatment with a radical hysterectomy, results from the SHAPE trial show.
-
From Awareness to Action: Putting Cancer Disparities in the Rearview MirrorEliminating disparities will require the efforts of people from across a broad spectrum of scientific research, according to leading experts, and must include working in concert with people and organizations in the community.
-
Stealing Strategies from Cancerous T Cells May Boost ImmunotherapyAdding a fusion of parts of two genes helped engineered T cells divide faster, kill more tumor cells, and survive longer in mice without making the T cells behave like cancer cells.
-
Nivolumab Injections Could Make Treatment Easier for More People with CancerIn a clinical trial, an injectable form of nivolumab (Opdivo) was as effective against kidney cancer as the intravenous form of the drug. Side effects were also similar and treatment time was shorter. Injectable immunotherapies, several experts said, if found to be comparable to IV forms, can be more convenient to receive and accessible to more people.
-
First Cancer TIL Therapy Gets FDA Approval for Advanced MelanomaIn an event more than three decades in the making, FDA has approved lifileucel (Amtagvi), the first cancer treatment that uses immune cells called tumor-infiltrating lymphocytes, or TILs.
-
Lutathera Shows Promise as Part of Initial Therapy for Some Neuroendocrine TumorsAdding Lu 177-dotate to the initial treatment of certain advanced neuroendocrine tumors nearly tripling the length of time people survive without their tumors getting worse, according to new clinical trial results.
-
ctDNA May Guide Who Needs Chemo After Colorectal Cancer SurgeryResults from a new study suggest that the presence of circulating tumor DNA (ctDNA) in blood samples can predict which patients with colorectal cancer should and shouldn’t get chemotherapy after surgery to remove their tumors.